SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.88% Passive Stake in Voyager Therapeutics

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.88% of Voyager Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") beneficially own 5,396,000 shares of Voyager Therapeutics, Inc. common stock.
• This ownership represents 9.88% of the company's outstanding common stock.
• The percentage is calculated based on 54,625,586 shares of Voyager Therapeutics, Inc. common stock outstanding as of October 28, 2024, as reported in the Issuer's Form 10-Q filed on November 12, 2024.
• Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of these shares.
• Steven Boyd, a United States citizen, is the managing member of Armistice Capital, LLC.
• Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over all 5,396,000 beneficially owned shares.
• The Reporting Persons certify that the shares were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of Voyager Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The filing is primarily a factual disclosure of beneficial ownership. The disclosure of a significant stake by an institutional investor can be viewed as a moderately positive signal of confidence in the company, although the filing itself is neutral in tone and purpose.

Positives

• The disclosure of a significant stake (9.88%) by an institutional investor like Armistice Capital, LLC and its principal, Steven Boyd, may signal confidence in Voyager Therapeutics, Inc.'s long-term prospects.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, indicating a passive investment intent, which can provide stability.

Risks

• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer. This mitigates the risk of an activist investor seeking to force immediate changes, but the nature of the holding could change in future filings.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future outlook.

Management Comments

• The Reporting Persons, Armistice Capital, LLC and Steven Boyd, certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing indicates a significant passive investment by a specialized investment firm in a biotechnology company. While the document itself does not provide industry analysis, such an investment suggests a belief in the long-term prospects of the therapeutics sector or the specific company's pipeline, aligning with broader trends of institutional capital allocation into life sciences.

Comparison to Industry Standards

• This document is a standard regulatory filing (Schedule 13G) for disclosing beneficial ownership exceeding 5% of a company's outstanding shares. It adheres to the disclosure requirements set forth by the SEC.
• The filing does not contain information for direct comparison to industry-specific operational or financial benchmarks, nor does it mention comparable companies, projects, or their results.

Related Party Transactions

• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, which is the direct holder of the reported shares. Steven Boyd is the managing member of Armistice Capital, LLC. This structure defines the beneficial ownership relationship for the reported securities.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an institutional investor may influence investor sentiment and perception of the company's value and stability.
• Management: Awareness of a large, passive institutional holder may influence strategic considerations, though the filing explicitly states no intent to influence control.

Next Steps

• The document does not outline any specific future actions, events, or milestones for Voyager Therapeutics, Inc. or the reporting persons beyond the ongoing passive holding of shares.

Key Dates

Keywords

Voyager Therapeutics, Armistice Capital, Steven Boyd, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology, Therapeutics